ReportWire

Ukraine officially approves medical cannabis quotas, “Cabinet of Ministers of Ukraine approves quotas for narcotic drugs and psychotropic substances for 2026” | Cannabis Law Report

Ministry of Health of Ukraine, posted 05 January 2026 10:38

The Government has adopted a resolution approving quotas for 2026 for the production, manufacture, storage, import, and export of narcotic drugs and psychotropic substances, as well as for the cultivation of plants containing such substances. The decision was made in accordance with Article 14 of the Law of Ukraine “On Narcotic Drugs, Psychotropic Substances and Precursors,” which establishes the annual determination of maximum quantities of controlled substances as a state measure to control their legal circulation.

The approved quotas are intended to meet the needs of medicine, pharmaceutical production, science, and education, prevent the leakage of narcotic drugs and psychotropic substances into illegal circulation, and fulfill Ukraine’s international obligations under the 1961, 1971, and 1988 UN Conventions. The approval of quotas is due not only to regulatory requirements, but also to the martial law and the increase in the number of patients who need drugs with controlled substances, in particular, soldiers with severe injuries.

For the first time, quotas have been set for substances based on medical cannabis. This refers to imports for use in scientific and scientific-technical activities, imports for the production (manufacture) of medicines and finished medicines included in the State Drug Register.

When calculating quotas, applications from licensed businesses, their production capabilities, and risks related to tetrahydrocannabinol (THC) were taken into account. Six medical cannabis-based substances are currently registered in Ukraine, with another 18 in the process of registration. The traceability of medical cannabis circulation is ensured through a unified accounting, registration, and control system that tracks all stages—from cultivation and production to sale to patients for medical reasons.

Quotas for methadone are set taking into account the needs of the substitution maintenance therapy program. As of November 2025, some 29,112 patients were receiving treatment.

Codeine quotas are determined based on domestic needs, exports, and potential growth in demand. Combined medicinal products containing small amounts of codeine and not subject to quotas are not included in the tables.

 

 

As posted by Falk Altenhoefer of Cannabis Start ups.com  on Linked In who writes

On January 5, 2026, Ukraine officially approved medical cannabis quotas for the first time.

A milestone that would have sounded aspirational not long ago is now reality.
Quotas now cover:
– imports
– scientific research
– pharmaceutical production

Six cannabis-based substances are already registered, 18 more are in the approval process, and distribution will be monitored through a digital control system aligned with UN conventions and legal clarity.

After years of war, the medical needs of Ukraine have fundamentally changed.

Severely injured soldiers and civilians require effective, modern pain therapies and Ukraine is responding pragmatically, responsibly, and human-centered.

For me, this moment carries special meaning.
In 2019, I spoke publicly for the first time at an International Medical Cannabis Conference, advocating for access, regulation, and patient-centered policy at a time when many still questioned whether this path was realistic at all.

 

Google AI says

The approval marks a critical implementation phase of the medical cannabis reform signed into law by President Volodymyr Zelensky in February 2024. Key details of the new 2026 quotas include: 

Sean Hocking

Source link